Group sequential testing of a treatment effect using a surrogate marker

DOI10.1093/BIOMTC/UJAE108MaRDI QIDQ7033582zbMATH OpenFDO

Authors Layla Parast, Jay Bartroff

Publication date 3 February 2025

Published in Biometrics (Search for Journal in Brave)

Full work available at URL https://doi.org/10.1093/BIOMTC/UJAE108

zbMATH Keywords

clinical trialfutility stoppinggroup sequential testingstopping boundariessurrogate marker

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Cites work

• A Measure of the Proportion of Treatment Effect Explained by a Surrogate Marker
• An overview of group sequential methods in longitudinal clinical trials
• Criteria for Surrogate End Points
• Evaluating surrogate marker information using censored data
• Group sequential designs for one-sided and two-sided hypothesis testing with provision for early stopping in favor of the null hypothesis
• scientific article; zbMATH DE number 1348603 (Why is no real title available?)
• scientific article; zbMATH DE number 7413954 (Why is no real title available?)
• Incorporating Surrogate Endpoints into Group Sequential Trials
• Nonparametric sequential testing in clinical trials with incomplete multivariate observations
• On group sequential tests for data in unequally sized groups and with unknown variance
• Predictive probability of success using surrogate endpoints
• Sequential experimentation in clinical trials. Design and analysis
• Using a surrogate marker for early testing of a treatment effect
• Using a surrogate with heterogeneous utility to test for a treatment effect

Cited in

(1)

• Surrogate marker evaluation: a tutorial using R

This page was built for publication: Group sequential testing of a treatment effect using a surrogate marker

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q7033582)